AGC Biologics Archives | Be Korea-savvy

Home / Posts tagged AGC Biologics

AGC Biologics and Gore Collaborate on New Protein A-based Purification Technology and Contract Manufacturing Services for Antibody Therapies

Seattle, Dec. 12 (Korea Bizwire) – AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a collaboration with W.L. Gore & Associates (Gore) that features Protein A affinity purification technology from Gore alongside the CDMO’s contract development and manufacturing services. By using GORE and AGC Biologics, biopharmaceutical companies can improve downstream purification processes [...]

AGC Biologics Receives Excellence in Innovation and Leadership by Italy’s Leading Business News Channel Le Fonti

Milan, Italy, Oct. 27 (Korea Bizwire) – AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced it received the Excellence in Innovation and Leadership Award from Italy’s leading business new channel, Le Fonti, at an award ceremony on October 6. The company was honored for the work of its Milan site, which helps [...]

AGC Biologics Honored for Innovations in Cell Line Development

Seattle, Oct. 13 (Korea Bizwire) — AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced it has been named a 2022 Leading Innovator in Mammalian Cell Line Development for the USA by Acquisition International. Recipients of this award are selected through a merit-based system that requires evidence of significant achievements [...]

AGC Biologics and Evax Partner to Advance Promising Equine Allergy Vaccine Candidate

Seattle, Sept. 7 (Korea Bizwire) – AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new partnership with Evax, a developer of equine vaccines to treat chronic diseases, respiratory disorders and allergies. Through this partnership, Evax advances its Antigen VLP Conjugate product into the clinical stage, and AGC Biologics will supply [...]

RoosterBio and AGC Biologics Announce Collaboration to Accelerate Manufacturing of Cell and Exosome Therapies

SEATTLE, Aug. 16 (Korea Bizwire) – AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced today a strategic partnership with RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cells (hMSCs), highly engineered media, and bioprocess development services. The partnership creates an end-to-end solution for the development and production of hMSC and exosome [...]

AGC Biologics Supports Altheia Science’s Gene Therapy Programs

SEATTLE, MILAN, July 28 (Korea Bizwire) – AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new partnership with Altheia Science, a gene therapy company pioneering cell and gene therapy strategies to treat autoimmune diseases and cancer. Through this partnership, Altheia Science will advance its development of autoimmunity treatments, focused on modulating [...]

AGC Biologics Named Manufacturing Company of the Year by American Business Awards

SEATTLE, June 29 (Korea Bizwire) – AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced it was named Company of the Year in the “Large – Manufacturing” category in the 20th Annual American Business Awards®. The American Business Awards are the U.S.A.’s premier business awards program. Nicknamed the Stevies for the [...]

AGC Biologics Honored as a Top 10 Company for Pharma Quality Assurance

SEATTLE, June 9 (Korea Bizwire) – AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced it has been named a Top 10 Top Quality Assurance Services provider by Pharma Tech Outlook Europe. The award, shared in the special Quality Assurance Edition (May 2022) of Pharma Tech Outlook Europe magazine, lists the top ten companies [...]

AGC Biologics Invests in New Viral Vector Suspension Capabilities at U.S. Cell & Gene Hub

SEATTLE, May 17 (Korea Bizwire) – AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced it is adding viral vector suspension technology and capacity for the development and manufacturing of gene therapies at its commercial-grade campus in Longmont, Col., USA. These new capabilities, which begin coming online in the third quarter of 2022, [...]

AGC Biologics Supports Omicron-based Vaccine Candidate Manufacturing with Starting Material

Heidelberg, Germany, Feb. 8 (Korea Bizwire) – AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced an expanded partnership to supply more plasmid DNA (pDNA) starting material for the Pfizer-BioNTech COVID-19 vaccine at the company’s Heidelberg facility. According to a recent news release from Pfizer and BioNTech, the companies have started to develop an Omicron-based [...]